The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a https://prestonforq301510.wikicorrespondent.com/6829634/retatrutide_vs_tirzepatide_a_comparative_analysis